A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node- Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

This randomized phase III clinical trial is studying chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies, such as trastuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. It is not yet known whether combination chemotherapy is more effective with trastuzumab in treating breast cancer.

Stanford is now accepting new patients for this trial. Please contact Donna Adelman at 650-724-1953 for more information.

Investigator(s):

Intervention(s):

  • biological : trastuzumab
  • drug : cyclophosphamide
  • drug : docetaxel
  • drug : doxorubicin hydrochloride
  • drug : paclitaxel
  • other : laboratory biomarker analysis

Phase: Phase 3

Eligibility

Ages Eligible For Study:

18 Years - N/A

External Links

Explore related trials

Contact information

Primary Contact:

Donna Adelman 650-724-1953

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: